NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Sunday. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ:NURO opened at $4.37 on Friday. The firm has a market cap of $8.91 million, a P/E ratio of -0.95 and a beta of 2.18. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73. The business’s 50 day simple moving average is $4.08 and its two-hundred day simple moving average is $3.96.

Institutional Trading of NeuroMetrix

An institutional investor recently bought a new position in NeuroMetrix stock. Renaissance Technologies LLC acquired a new stake in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix at the end of the most recent reporting period. 19.40% of the stock is owned by institutional investors.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.